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Abstract
Background: Strong evidence implicates inflammation in the development of atherosclerotic heart disease but less
is known about peripheral arterial disease (PAD). Our objective was to test the hypothesis that a composite index of
inflammatory burden is associated with PAD.
Methods: Cross-sectional analysis of a randomly-selected group of 903 community-dwelling men in the MrOS
cohort recruited between 2000 and 2002. Using blood samples, we measured seven cytokines and related these
levels to prevalent PAD (ankle-brachial index (ABI) <0.9) both individually and as part of an “inflammatory burden
score” (a composite sum of the number of pro-inflammatory cytokines in the highest quartile).
Results: Overall, 6.75% of men had ABI <0.9. The odds of prevalent PAD were higher in men with the highest
quartile (Q4) levels of interleukin-6 multivariable (MV) adjusted (odds ratio (OR) =3.95 (95% CI, 1.4–11.3), tumor
necrosis factor alpha OR = 4.44 (95% confidence interval (CI), 1.5–12.8), and C-reactive protein OR = 3.63 (95% CI,
1.4–9.4) compared to men in Q1. The magnitude of the association of these cytokines with PAD was similar to
the effect of being 10 years older, OR = 2.41 (95% CI, 1.16–3.7). These significant effects persisted after additional
MV adjustment for smoking except for CRP. Men with the highest inflammatory burden score (≥3) had 3.6 (95% CI,
1.5–8.7) increased odds of PAD, p trend = 0.03. After smoking adjustment the linear trend was borderline statistically
significant (p trend = 0.10).
Conclusion: Inflammatory burden is associated with prevalent PAD, an association similar to aging 10 years. The
inflammatory effects of smoking contributes to the underlying association between inflammation and PAD.
Keywords: Peripheral arterial disease, Peripheral vascular disease, Inflammation, Cytokine, Ankle-arm index, Ankle-brachial
index, Smoking, Men
Background
Peripheral arterial disease (PAD) affects more than 8
million Americans and its prevalence is likely to increase
as the population ages [1]. Not only is the disease linked
to significantly impaired physical function and quality of
life [2–4] but considerable evidence supports a higher
risk of mortality in patients with PAD [5, 6], particularly
from cardiovascular causes [7, 8]. The ankle brachial
index (ABI), which is the ratio of systolic pressure at
posterior tibial and/or dorsalis pedis arteries divided by
the brachial systolic blood pressure, is commonly used
to measure PAD in the legs. Interestingly, incorpor-
ation of the ABI [6] into risk stratification tools such
as Framingham Risk Score (includes age, total and high
density lipoprotein cholesterol, blood pressure, diabetes
and smoking) was found to nearly double the accuracy of
10-year predictions of total mortality, cardiovascular
mortality, and major coronary events [6].
A number of recent studies have found pro-inflammatory
cytokines to be strongly linked to prevalent PAD [9–11] as
well as its severity [12, 13] even after adjusting for trad-
itional cardiovascular risk factors [10, 13–15]. While the
mechanisms remain unknown, certain pro-inflammatory
cytokines, such as interleukin-6 (IL-6) and tumor-necrosis
factor-α (TNFα), TNF soluble receptor-II (TNFαSRII),
appear to be associated with PAD independent of one
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another [15]. Some inflammatory markers show different
relationships with PAD in the context of disease, as is the
case with C-reactive protein (CRP) and diabetes [16].
The exact pathophysiology of PAD remains unclear,
but inflammation appears to be involved. Previous studies
relating inflammatory markers to PAD had small sample
sizes or included only a few inflammatory cytokines. Using
data collected in the Osteoporotic Fractures in Men
Study (MrOS), we evaluated the relation of 7 inflammatory
markers - CRP, IL-6, IL-6 soluble receptor (IL-6SR), TNFα,
TNFαSRI, and TNFαSRII as well as interleukin-10 (IL-10,
anti-inflammatory), to prevalent PAD in older men and




In 2000–2002, 5994 men enrolled in the Osteoporotic
Fractures in Men Study (MrOS), a longitudinal cohort
study designed to determine risk factors for osteoporosis,
fracture and falls. Men were recruited at six US academic
clinical centers primarily through mass mailings targeted
to age eligible men. The MrOS study is described in more
detail in other publications [17, 18]. Briefly, all men were
age ≥ age 65, able to walk independently and did not
report bilateral hip replacements; 35% of men were
age 65–59 and 11% age 80 or older at baseline. The
study was approved by the Institutional Review Boards at
each institution. All participants provided written informed
consent.
The current analysis was limited to a cohort of 1,530
randomly-selected participants. Men with at least 5, 1-mL
aliquots of archived, unthawed serum were eligible for in-
clusion. Of these, 980 participants had cytokine data. These
men were from a randomly selected subcohort of MrOS
men who had inflammatory markers measured as part of a
case-cohort study of inflammation and fracture [19]. In
order to assign an inflammatory burden score (see below),
we excluded 46 participants with missing cytokine data.
We further excluded 31 participants with missing ABI
values and additional 25 participants with ABI > =1.4,
rendering an analytic sample of 878.
Measurements at baseline visit
Biochemical measurements
Fasting morning blood samples were obtained at the base-
line visit and were processed and stored at -120C until
assay. All cytokine assays were performed at the Laboratory
for Cytokine Biochemistry (LCBR), University of Vermont,
under the direction of Dr. Russell Tracy.
IL-6 was measured using a high sensitivity ELISA from
R&D Systems (Minneapolis, MN) employing a quantitative
sandwich enzyme immunoassay technique. The assay
range is 0.16–12.0 pg/mL with inter-assay coefficients
of variability (CVs) ranging from 6.11–8.47%. Ex-
pected values for IL-6 in normal, healthy individuals
are <10 pg/mL.
IL-6sR, TNFαSRI and TNFαSRII were measured using
an ELISA from R&D Systems (Minneapolis, MN). A
monoclonal antibody specific for each cytokine receptor
was coated on the assay plate and a polyclonal anti- cyto-
kine receptor antibody used as the sandwich antibody; the
amount of cytokine receptor was then determined by
colorimetric reaction. The assay range for IL-6sR was
3120–200,000 pg/mL. The manufacturer normal range
for IL-6 is approximately 15,000-46,000 pg/mL with
inter-assay CVs ranging from 4.68–8.83%. The assay
range for TNFα SRI and SRII is 78–6000 pg/mL with
inter-assay CVs ranging from 5.42–8.59% for TNFαSRI
and 2.87–3.54% for TNFαSRII.
IL-10 and TNFα were measured using the Human
Serum CVD3 Multiplex Kit from Millipore Corp. (Billerica,
MA), using flow cytometry on the Bio-Rad Bioplex 200
Luminex instrument. The assay range for IL-10 is 0.13-
2000 pg/mL with inter-assay CVs ranging from 4.94–
10.66%. The TNFα assay range is 0.13-2000 pg/mL with
inter-assay CVs ranging from 4.93–9.13%.
CRP was measured using the BNII nephelometer from
Dade Behring utilizing a particle enhanced immunone-
pholometric assay. The assay range is 0.16–1100 ug/mL.
Expected values for CRP in normal, healthy individuals
are ≤ 3 ug/mL. Inter-assay CVs ranged from 1.52–3.68%.
Participants were assigned a pro-inflammatory burden
score –a composite variable that was the sum of the
number of pro-inflammatory cytokines (IL-6, IL-6 SR,
TNFα, TNFαSRI, TNFαSRII, CRP) in the highest quartile.
Of the 878 men in our analytic sample, 851(97%) had data
on all 6 inflammatory markers and an additional 26 men
had data on 5 cytokines. Based on the pro-inflammatory
burden score, participants were classified into 4 groups
according to the number of pro-inflammatory cytokines
in the highest quartile as follows: 0, 1, 2, and 3–6 (≥3).
Other published studies have found relationships between
inflammatory burden scores and hip fracture [20].
Outcome measurements
The systolic blood pressure in the right and left posterior
tibial artery and the right brachial artery were measured
twice after the subjects were supine for at least 5 min. The
pulses were detected by using a hand held 8 MHz doppler.
The resting ABI was calculated in each leg as the average
of the 2 measures of the posterior tibial pressure divided
by the average of the two brachial measures. The lower of
the right and left index was used as a measure of lower
extremity PAD [21]. Participants with an ABI < 0.90 were
classified as having PAD, while those with an ABI ≥0.90
were considered free of disease [6].
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Covariates
Height was measured by Harpenden stadiometer; weight,
by digital or balance beam scale. Body mass index (BMI)
was calculated as weight in kilograms divided by height in
meters squared. Biomarkers included systolic blood pres-
sure (average of two measurements in the arm), fasting
blood glucose, total cholesterol and HDL. Walking speed
was determined by time to complete a 6-m course at the
participant’s usual walking speed [18].
A self-administered questionnaire included demo-
graphics, education, self-rated health status, medical
history, tobacco use (pack-years and current smoking/
past smoking status), and alcohol consumption. Par-
ticipants were asked to bring all prescription medica-
tions they had been taking for at least 1 month to the
clinic visit. All medications were entered into an electronic
database, verified by pill bottle examination, and each medi-
cation was matched to its ingredients based on the Iowa
Drug Information Service (IDIS) Drug Vocabulary (College
of Pharmacy, University of Iowa, Iowa City, IA) [22]. Partic-
ipants were classified as diabetic by self-report, a fasting
blood glucose (FBG) ≥126 mg/dL, or if they had prescrip-
tions for hypoglycemic agents. Pre-diabetes was defined as
FBG ≥100 mg/dL and <126 mg/dL, while normoglycemia
was defined as blood glucose <100 mg/dL. Physical activity
was quantified using the Physical Activity Scale for the
Elderly (PASE) [23].
Statistical analysis
We calculated descriptive statistics for all variables and
tabulated characteristics of participants by level of pro-
inflammatory burden score testing for trend. Next, we
compared participants with and without PAD. For this, we
used chi-squared test (or Fisher's exact test) for categorical
variables, two-sample t test for normally distributed
continuous data and Wilcoxon-Mann–Whitney test for
skewed continuous data. Median tests were used for the
cytokines variables because of skewed distributions. Then,
a series of crude, age-adjusted and multivariable-adjusted
logistic regression models of the relationship between each
cytokine and PAD were fit. We modeled quartiles of cyto-
kines as dummy variables (1–4) with quartile 1 as the refer-
ent. For the inflammatory burden logistic regressions, we
also used dummy variables to account for the number of
“high” inflammatory cytokines (0, 1, 2, ≥3). The multivari-
able models were adjusted for variables that were signifi-
cantly different between men with and without PAD and
variables that are related to both PAD and inflammation.
All statistical analyses were conducted with Stata version
13.1 (StataCorp LP, College Station, TX, USA).
Results
Descriptive characteristics of study participants by in-
flammatory burden score (0 to ≥3) are shown in Table 1.
The largest percentage of participants (35%) had a score of
0, followed by a score of 1 (26%), 2 (15%) and ≥3 (24%).
With increasing inflammatory burden score, the preva-
lence of PAD as measured by ABI increased. Men with the
highest inflammatory burden also tended to be older and
were less likely to rate their health status as good or excel-
lent. Fasting blood glucose tended to increase but total
cholesterol and HDL tended to decrease with increasing
inflammatory burden. Men with three or more cytokines
measured in the highest quartile had a higher prevalence
of multiple medical conditions including history of myo-
cardial infarction, hypertension, chronic obstructive pul-
monary disease (COPD), congestive heart failure (CHF)
and diabetes when compared to those with a score of 0
or 1. A higher proportion of participants with the highest
inflammatory burden were unable to walk faster than
0.8 m/s. There was no difference in use of aspirin or
non-steroidal anti-inflammatory drugs (NSAIDs) across
inflammatory burden but use of ACE inhibitors, loop
diuretics and antidepressants was greatest among men
with the greatest inflammatory burden. On average,
men with the highest inflammatory burden also tended
to drink less alcohol and have a greater number of
smoking pack-years.
Men with PAD (6.75%) had higher median levels of the
pro-inflammatory cytokines IL-6, IL-10, TNFα, TNFαSRI,
TNFαSRII, and CRP; they were almost twice as likely to
have a CRP level above the clinical cutoff of 3ug/mL
(p < 0.05), Table 2. They were also older, and less likely
to report good/excellent health status, had higher rates
of hypertension, and CHF. Systolic blood pressure and
fasting glucose were significantly higher in men with PAD.
BMI was lower in the PAD group. There was no difference
in NSAIDs, aspirin use, Cox inhibitors or alcohol use by
PAD status. Men with ABI <0.9 were more likely to report
use of ACE inhibitors, loop diuretics and antidepressants
(p = 0.08).
Men with PAD were 4.4 times more likely to be cur-
rently smoking that those without the disease; they also
had nearly twice the number of smoking pack-years.
Trends between quartile levels of various cytokines
and prevalent PAD are shown in Table 3. Current smoking
status was added separately to multivariate adjustment
because it was found to have an important influence on
odds ratios.
There were higher odds of prevalent PAD among par-
ticipants with increasing levels of IL-6, TNFα, and CRP.
These trends remained statistically significant (p <0.05)
in MV models, except in the case of CRP, which was
attenuated after multivariate plus smoking status adjust-
ment. For IL-6, in MV models, the odds ratios ranged from
1.37 (quartile 2) to 3.95 (quartile 4), p trend = 0.003; for
TNFα, 3.02 (quartile 2) to 4.44 (quartile 4), p trend = 0.05;
and for CRP, 2.61 (quartile 2) to 3.63 (quartile 4), p trend =
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0.02. These increased odds of prevalent PAD were similar
to aging 10 years (OR per ten year increase in age = 2.41
(1.57 - 3.70). A positive trend between TNFαSRI and
TNFαSRII was found with PAD for crude and age-adjusted
models; however, this was no longer statistically significant
after multivariate adjustment or smoking adjustment. The
association with IL-6 SR and Il-10 with PAD were no
longer significant in the age adjusted models. Adjustment
for cardiovascular risk factors had little effect on the associ-
ation between inflammatory burden and PAD.
Men with CRP >3ug/mL were more likely to have preva-
lent PAD than those with a lower level, MV models, OR =
2.0, (95% CI, 1.06–3.79). Nevertheless, this association was
no longer significant after adjusting for pack-years or
Table 1 Characteristics of participants according to number of pro-inflammatory cytokines in the highest quartile
Characteristics Total
N = 878









PAD, ABI <0.90, n (%) 61 (6.95) 12 (3.97) 14 (6.09) 5 (3.82) 30 (13.95) <0.001
Demographics
Age, years, mean ± SD 73.71 ± 5.87 72.82 ± 5.39 72.44 ± 5.13 74.22 ± 6.10 75.99 ± 5.87 <0.001
Non-white race, n (%) 67 (7.63) 29 (9.60) 21 (9.13) 7 (5.34) 10 (4.65) 0.019
High school or less, n (%) 217 (24.72) 56 (18.54) 59 (25.65) 40 (30.53) 62 (28.84) 0.003
Health status
Self-rated health status, good/excellent, n (%) 753 (85.86) 275 (91.06) 201 (87.39) 111 (85.38) 166 (77.21) <0.001
Body Mass Index (BMI), mean ± SD 27.32 ± 3.56 27.22 ± 3.17 27.06 ± 3.72 27.39 ± 3.57 27.69 ± 3.86 0.146
Systolic blood pressure (mmHG), mean ± SD 139.09 ± 18.92 138.94 ± 18.44 138.60 ± 18.59 138.58 ± 18.06 140.13 ± 20.47 0.555
Fasting blood glucose (mg/dL), mean ± SD 106.68 ± 24.90 105.20 ± 21.53 104.22 ± 22.69 109.37 ± 32.89 109.75 ± 25.53 0.027
Total cholesterol (mg/dL), mean ± SD 194.58 ± 32.84 196.43 ± 32.52 196.78 ± 32.69 196.30 ± 36.28 188.59 ± 30.62 0.021
HDL (mg/dL), mean ± SD 48.96 ± 14.65 51.05 ± 14.39 49.85 ± 15.46 48.35 ± 13.75 45.46 ± 14.11 <0.001
Medical conditions
Myocardial infarction, n (%) 139 (15.83) 41 (13.58) 29 (12.61) 20 (15.27) 49 (22.79) 0.005
Hypertension, n (%) 383 (43.62) 122 (40.40) 84 (36.52) 56 (42.75) 121 (56.28) <0.001
Congestive heart failure, n (%) 36 (4.10) 7 (2.32) 5 (2.17) 4 (3.05) 20 (9.30) <0.001
Chronic obstructive pulmonary disease, n (%) 97 (11.05) 17 (5.63) 26 (11.30) 17 (12.98) 37 (17.21) <0.001
Diabetes status 0.002
Diabetes, n (%) 142 (16.69) 39 (13.36) 25 (11.21) 24 (18.75) 54 (25.96)
Pre-diabetes, n (%) 310 (36.43) 114 (39.04) 79 (35.43) 44 (34.38) 73 (35.10)
Medication use
NSAID, n (%) 130 (15.51) 44 (15.28) 26 (11.82) 19 (15.45) 41 (19.81) 0.137
Aspirin, n (%) 284 (33.89) 97 (33.68) 73 (33.18) 32 (26.02) 82 (39.61) 0.366
Cox-II inhibitor, n (%) 63 (7.52) 20 (6.94) 11 (5.00) 10 (8.13) 22 (10.63) 0.090
ACE inhibitors, n (%) 166 (19.81) 53 (18.40) 30 (13.64) 24 (19.51) 59 (28.50) 0.004
Loop diuretics, n (%) 38 (4.53) 1 (0.35) 6 (2.73) 4 (3.25) 27 (13.04) <0.001
Antidepressants, n (%) 55 (6.65) 15 (5.26) 13 (6.07) 3 (2.46) 24 (11.65) 0.022
Physical performance
Physical Activity Scale for the Elderly score, mean ± SD 149.92 ± 69.95 155.79 ± 66.48 158.76 ± 67.01 147.00 ± 65.49 134.02 ± 77.68 <0.001
Walking speed <0.8 meters/seconds, n (%) 28 (3.19) 7 (2.32) 3 (1.30) 3 (2.29) 15 (6.98) 0.004
Average number of drinks/week, mean ± SD 4.52 ± 6.90 5.23 ± 7.20 4.78 ± 7.25 3.61 ± 5.82 3.82 ± 6.60 0.001
Smoking status 0.010
Current smoker, n (%) 33 (3.76) 6 (1.99) 7 (3.04) 7 (5.34) 13 (6.05)
Past smoker, n (%) 514 (58.54) 172 (56.95) 134 (58.26) 74 (56.49) 134 (62.33)
Smoking pack-years, mean ± SD 18.97 ± 25.71 16.09 ± 23.86 18.09 ± 24.74 18.04 ± 22.40 24.53 ± 30.07 0.003
aComposite variable summing number of pro-inflammatory cytokines (IL-6, IL-6 SR, TNFα, TNFαSRI, TNFαSRII, CRP) in the highest quartile
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Table 2 Characteristics of men with and without peripheral arterial disease
Characteristics Total N = 878 Men with PAD
(ABI <0.90) N = 61
Men without PAD
(ABI ≥0.90) N = 817
p-valuea
Cytokines
IL-6 pg/ml, median (interquartile range) 2.40 (1.84) 3.38 (2.16) 2.34 (1.71) <0.001
IL-6 SR pg/ml, median (interquartile range) 48636 (18103) 50655 (19051) 48494 (18064) 0.232
IL-10 pg/ml, median (interquartile range) 8.98 (6.94) 10.62 (5.69) 8.87 (6.86) 0.012
TNFα pg/ml, median (interquartile range) 3.95 (2.43) 4.55 (2.24) 3.91 (2.41) 0.032
TNFαSRI pg/ml, median (interquartile range) 1918.50 (586.90) 2210.50 (853.10) 1900.70 (570.10) 0.002
TNFαSRII pg/ml, median (interquartile range) 3499.80 (952.10) 3856.85 (1202.90) 3482.10 (922.70) 0.029
CRP ug/ml, median (interquartile range) 1.40 (2.12) 2.24 (3.94) 1.37 (2.08) 0.042
CRP >3 ug/mL, n (%) 209 (23.94) 24 (40.68) 185 (22.73) 0.002
Demographics
Age, years, mean ± SD 73.71 ± 5.87 76.70 ± 5.99 73.48 ± 5.99 <0.001
None-white race, n (%) 67 (7.63) 4 (6.56) 63 (7.71) 1.000
High school or less, n (%) 217 (24.72) 19 (31.15) 198 (24.24) 0.227
Health status
Self-rated health status, good/excellent, n (%) 753 (85.86) 44 (72.13) 709 (86.89) 0.001
Body Mass Index (BMI), mean ± SD 27.32 ± 3.56 26.05 ± 3.25 27.42 ± 3.56 0.004
Systolic blood pressure (mmHG), mean ± SD 139.09 ± 18.92 148.21 ± 24.13 138.41 ± 18.31 <0.001
Fasting blood glucose (mg/dL), mean ± SD 106.68 ± 24.90 117.80 ± 41.47 105.83 ± 22.97 0.039
Total cholesterol (mg/dL), mean ± SD 194.58 ± 32.84 191.44 ± 32.46 194.82 ± 32.87 0.442
HDL (mg/dL), mean ± SD 48.96 ± 14.65 48.32 ± 15.85 49.01 ± 14.57 0.435
Medical conditions
Myocardial infarction, n (%) 139 (15.83) 9 (14.75) 130 (15.91) 0.811
Hypertension, n (%) 383 (43.62) 39 (63.93) 344 (42.11) 0.001
Congestive heart failure, n (%) 36 (4.10) 7 (11.48) 29 (3.55) 0.003
Chronic obstructive pulmonary disease, n (%) 97 (11.05) 8 (13.11) 89 (10.89) 0.593
Diabetes status 0.071
Diabetes, n (%) 142 (16.69) 16 (26.67) 126 (15.93)
Pre-diabetes, n (%) 310 (36.43) 22 (36.67) 288 (36.41)
Medication use
NSAID, n (%) 130 (15.51) 10 (17.54) 120 (15.36) 0.661
Aspirin, n (%) 284 (33.89) 20 (35.09) 264 (33.80) 0.843
Cox-II inhibitor, n (%) 63 (7.52) 1 (1.75) 62 (7.94) 0.115
ACE inhibitors, n (%) 166 (19.81) 18 (31.58) 148 (18.95) 0.021
Loop diuretics, n (%) 38 (4.53) 8 (14.04) 30 (3.84) <0.001
Antidepressants, n (%) 55 (6.65) 7 (12.28) 48 (6.23) 0.077
Physical performance
Physical Activity Scale for the Elderly (PASE) score, mean ± SD 149.92 ± 69.95 130.25 ± 79.94 151.39 ± 68.98 0.008
Walking speed <0.8 meters/seconds, n (%) 28 (3.19) 6 (9.84) 22 (2.69) 0.002
Average number of drinks/week, mean ± SD 4.52 ± 6.90 4.77 ± 7.79 4.51 ± 6.84 0.275
Smoking status <0.001
Current smoker, n (%) 33 (3.76) 8 (13.11) 25 (3.06)
Past smoker, n (%) 514 (58.54) 40 (65.57) 474 (58.02)
Smoking pack-years, mean ± SD 18.97 ± 25.71 33.64 ± 32.44 17.87 ± 24.81 <0.001
aBased on median test for cytokines variables, two-sample t test (or Wilcoxon-Mann–Whitney test) for other continuous variables and chi-squared test (or Fisher's
exact test) for categorical variables
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smoking status (Table 4). Participants with an inflam-
matory burden score ≥3 (Table 5) were 3.6 times more
likely to have PAD compared to those with a score of 0,
OR = 3.59 (95% CI, 1.48–8.71). This trend was attenuated
slightly after adjustment for smoking, (p trend = 0.09).
Discussion
In the present study men with the highest levels of IL-6,
TNF-α, or CRP had a higher odds of prevalent PAD
compared to men with the lowest levels. Higher inflam-
mation was associated with slower walking speed as well
Table 3 Association between cytokines and prevalent peripheral arterial disease (ABI <0.90)
Second quarter




(75th - 100th percentile)
P for
trend
Cytokine Model Odds Ratio, 95% Confidence Intervala
IL-6 Crude model 1.94 (0.65, 5.87) 3.63 (1.31, 10.01) 6.00 (2.27, 15.91) <0.001
Age-adjusted model 1.71 (0.57, 5.12) 3.13 (1.12, 8.71) 4.91 (1.83, 13.17) 0.001
Multivariate-adjusted modelb 1.37 (0.42, 4.46) 3.46 (1.19, 10.11) 3.95 (1.38, 11.26) 0.003
Multivariate-adjusted model + smoking status 1.32 (0.40, 4.31) 2.88 (0.98, 8.49) 2.90 (0.99, 8.52) 0.020
Multivariate-adjusted model + CVD risk factorsc 1.17 (0.34, 3.98) 3.39 (1.13,10.18) 3.57 (1.21, 10.50) 0.005
IL-6 SR Crude model 0.95 (0.42, 2.13) 1.11 (0.51, 2.43) 1.71 (0.84, 3.48) 0.129
Age-adjusted model 0.93 (0.41, 2.10) 1.07 (0.49, 2.35) 1.61 (0.78, 3.31) 0.180
Multivariate-adjusted modelb 1.16 (0.46, 2.89) 1.12 (0.47, 2.71) 1.65 (0.73, 3.74) 0.270
Multivariate-adjusted model + smoking status 1.24 (0.49, 3.18) 1.31 (0.52, 3.28) 1.85 (0.79, 4.36) 0.170
Multivariate-adjusted model + CVD risk factorsc 1.12 (0.44, 2.89) 1.03 (0.41, 2.59) 1.86 (0.79, 4.34) 0.204
IL-10 Crude model 1.30 (0.53, 3.14) 2.73 (1.23, 6.05) 1.89 (0.82, 4.34) 0.045
Age-adjusted model 1.27 (0.52, 3.11) 2.55 (1.14, 5.68) 1.63 (0.70, 3.79) 0.107
Multivariate-adjusted modelb 1.48 (0.56, 3.93) 2.02 (0.81, 5.04) 1.57 (0.62, 3.96) 0.263
Multivariate-adjusted model + smoking status 1.52 (0.56, 4.13) 2.13 (0.83, 5.44) 1.75 (0.68, 4.53) 0.184
Multivariate-adjusted model + CVD risk factorsc 1.74 (0.63, 4.81) 2.52 (0.96, 6.57) 1.89 (0.72, 4.95) 0.139
TNFα Crude model 2.33 (0.93, 5.83) 2.52 (1.02, 6.21) 3.24 (1.35, 7.79) 0.010
Age-adjusted model 2.43 (0.97, 6.13) 2.54 (1.02, 6.28) 3.09 (1.27, 7.47) 0.015
Multivariate-adjusted modelb 3.02 (0.99, 9.18) 3.69 (1.26, 10.78) 4.44 (1.54, 12.80) 0.005
Multivariate-adjusted model + smoking status 2.95 (0.96, 9.06) 3.40 (1.15, 10.08) 3.95 (1.35, 11.58) 0.012
Multivariate-adjusted model + CVD risk factorsc 3.37 (1.05, 10.83) 4.13 (1.35, 12.67) 5.34 (1.77, 16.16) 0.003
TNFαSRI Crude model 1.15 (0.47, 2.84) 1.54 (0.65, 3.64) 3.34 (1.53, 7.29) 0.002
Age-adjusted model 1.01 (0.41, 2.51) 1.25 (0.52, 2.99) 2.24 (0.97, 5.15) 0.051
Multivariate-adjusted modelb 1.24 (0.46, 3.34) 1.28 (0.48, 3.42) 2.26 (0.89, 5.75) 0.104
Multivariate-adjusted model + smoking status 1.16 (0.42, 3.16) 1.07 (0.39, 2.89) 1.80 (0.69, 4.69) 0.285
Multivariate-adjusted model + CVD risk factorsc 1.43 (0.50, 4.13) 1.59 (0.56, 4.52) 3.20 (1.15, 8.85) 0.029
TNFαSRII Crude model 1.83 (0.72, 4.68) 1.95 (0.77, 4.94) 3.74 (1.57, 8.88) 0.004
Age-adjusted model 1.64 (0.64, 4.21) 1.64 (0.64, 4.20) 2.65 (1.08, 6.54) 0.042
Multivariate-adjusted modela 1.79 (0.63, 5.06) 1.70 (0.60, 4.83) 2.50 (0.91, 6.85) 0.095
Multivariate-adjusted model + smoking status 1.50 (0.52, 4.33) 1.46 (0.50, 4.20) 2.11 (0.75, 5.91) 0.181
Multivariate-adjusted model + CVD risk factorsc 2.23 (0.72, 6.93) 2.66 (0.85, 8.32) 3.81 (1.25, 11.63) 0.019
CRP Crude model 1.78 (0.73, 4.32) 1.53 (0.61, 3.82) 3.37 (1.48, 7.64) 0.008
Age-adjusted model 1.92 (0.78, 4.71) 1.66 (0.66, 4.18) 3.43 (1.50, 7.85) 0.008
Multivariate-adjusted modelb 2.61 (0.95, 7.15) 1.88 (0.66, 5.36) 3.63 (1.41, 9.36) 0.020
Multivariate-adjusted model + smoking status 2.41 (0.87, 6.66) 1.52 (0.52, 4.44) 2.80 (1.06, 7.37) 0.092
Multivariate-adjusted model + CVD risk factorsc 2.02 (0.71, 5.73) 1.62 (0.56, 4.71) 3.24 (1.23, 8.55) 0.035
aReference group = lowest quartile
bMultivariate-adjusted models were adjusted for age, MI, hypertension, CHF, COPD, diabetes status, NSAID, Aspirin, cox-II inhibitor, ACE inhibitors, loop diuretics,
antidepressants, self-rated health status, BMI, PASE score and walking speed
cCVD risk factors included systolic blood pressure, fasting blood glucose, total cholesterol and HDL
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as a higher prevalence of hypertension, diabetes mellitus,
COPD, CHF and higher fasting blood glucose. Neverthe-
less, the association between inflammation and PAD was
independent of these risk factors. Smoking is a well-
established risk factor for PAD and was also associated
with greater inflammation. Adjustment for smoking attenu-
ated the relationship between CRP and PAD, suggesting
that smoking may influence risk of PAD through inflamma-
tory pathways. Conversely, the association between IL-6
and TNFα and PAD remained statistically significant even
after adjusting for smoking, supporting previous studies
suggesting that inflammation itself is an independent risk
factor for PAD [9, 10, 12–14, 24]. In our study, the
magnitude of the association between highest inflam-
matory burden and PAD was similar to the increased
odds of PAD associated with being 10 years older.
Men with PAD tended to have higher levels of every
pro-inflammatory cytokine except IL-6 SR. Current
literature supports that the strongest positive associa-
tions between PAD and cytokines are found with IL-6
[9, 13, 15, 25, 26] and CRP [9, 11, 13, 15, 26, 27]
although there is some evidence for IL-6SR [9],
TNFαSRI/II [15, 28] and a number of cytokines we did
not measure in our study [9, 13, 29]. Our finding that
TNFα was positively and significantly related with
PAD has some strong support [26], although certain
studies lack statistical significance [15] and others
have actually reported the opposite [9]. Although pre-
vious studies have found conflicting results [9, 10, 30]
we found a positive relationship between IL-10 and PAD
in unadjusted analyses, which may represent a mechanism
of overall inflammatory dysregulation in the disease. We
found no association between IL-6SR and PAD, and the
positive association between TNFαSRI/II with PAD was
attenuated after multivariate adjustment. Nevertheless,
our metric of inflammatory burden included all of the
pro-inflammatory markers. Men with the greatest inflam-
matory burden had a >3-fold increased odds of PAD, but
this was slightly attenuated after adjusting for smoking.
These results suggest that overall inflammatory burden is
related to PAD; however, smoking at least partially medi-
ates this association.
Pro-inflammatory cytokines are implicated in other
disease processes but the exact mechanism of their
pathophysiology remains unclear. If particular inflammatory
profiles are specific to one disease process over another
(i.e. PAD versus CVD) it could lead to new screening
Table 4 Association between CRP >3 ug/mL and prevalent
peripheral arterial disease (ABI <0.90)
Model CRP >3 ug/mL
Odds Ratio (95%
Confidence Interval)a
Crude model 2.33 (1.35, 4.02)
Age-adjusted model 2.24 (1.29, 3.90)
Conditions-adjusted modelb 2.23 (1.26, 3.96)
Medications-adjusted modelc 2.20 (1.23, 3.96)
Multivariate-adjusted modeld 2.00 (1.06, 3.79)
Multivariate-adjusted model + smoking status 1.69 (0.88, 3.25)
Multivariate-adjusted model + smoking pack-years 1.69 (0.87, 3.26)
Multivariate-adjusted model + CVD risk factorse 2.02 (1.04, 3.92)
aReference group = CRP ≤3 ug/mL
bConditions-adjusted model was adjusted for MI, hypertension, CHF, COPD,
diabetes status
cMedications-adjusted model was adjusted for NSAID, Aspirin, cox-II inhibitor,
ACE inhibitors, loop diuretics, antidepressants
dMultivariate-adjusted models were adjusted for age, MI, hypertension, CHF,
COPD, diabetes status, NSAID, Aspirin, cox-II inhibitor, ACE inhibitors, loop
diuretics, antidepressants, self-rated health status, BMI, PASE score, walking speed
eCVD risk factors included systolic blood pressure, fasting blood glucose, total
cholesterol and HDL
Table 5 Association of pro-inflammatory burden scores with prevalent peripheral arterial disease
Model Pro-inflammatory burden score
Odds Ratio (95% Confidence Interval)a
1 2 ≥3 P for trend
Crude model 1.57 (0.71, 3.45) 0.96 (0.33, 2.78) 3.92 (1.96, 7.85) 0.002
Age-adjusted model 1.62 (0.73, 3.59) 0.85 (0.29, 2.48) 3.11 (1.52, 6.35) 0.025
Conditions-adjusted modelb 1.79 (0.79, 4.06) 1.01 (0.34, 2.98) 3.65 (1.75, 7.63) 0.008
Medications-adjusted modelc 2.13 (0.90, 5.06) 1.30 (0.42, 3.98) 4.29 (1.93, 9.54) 0.004
Multivariate-adjusted modeld 2.40 (0.95, 6.07) 1.27 (0.39, 4.15) 3.59 (1.48, 8.71) 0.031
Multivariate-adjusted model + smoking status 2.25 (0.87, 5.78) 1.15 (0.35, 3.79) 2.88 (1.17, 7.13) 0.097
Multivariate-adjusted model + smoking pack-years 2.42 (0.93, 6.27) 1.28 (0.38, 4.25) 3.29 (1.33, 8.15) 0.052
Multivariate-adjusted model + CVD risk factorse 2.87 (1.06, 7.79) 1.31 (0.37, 4.67) 4.88 (1.86, 12.79) 0.013
aReference group = pro-inflammatory burden score of zero
bConditions-adjusted model was adjusted for MI, hypertension, CHF, COPD, diabetes status
cMedications-adjusted model was adjusted for NSAID, Aspirin, cox-II inhibitor, ACE inhibitors, loop diuretics, antidepressants
dMultivariate-adjusted models were adjusted for age, MI, hypertension, CHF, COPD, diabetes status, NSAID, Aspirin, cox-II inhibitor, ACE inhibitors, loop diuretics,
antidepressants, self-rated health status, BMI, PASE score, walking speed
eCVD risk factors included systolic blood pressure, fasting blood glucose, total cholesterol and HDL
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tools, parameters for risk stratification, and targeted
therapies. With an aging population and large anticipated
influx of new “health care utilizers”, it is of paramount
importance that screening tests be developed and
exploited to curb morbidity and mortality from PAD
and other diseases. Development of a screening cytokine
panel to identify patients at risk of multiple diseases would
have an important public health impact.
There are a number of strengths to our study. Our
study consists of a population-based cohort and we
measured seven cytokines with well-established, repeatable
assays. Our use of ABI as a proxy for PAD is widely
accepted [6] and we accounted for many possible con-
founders, including standard cardiovascular risk fac-
tors, physical activity, comorbidities and medications.
Previous literature on PAD and inflammation often used a
case–control approach or measured only a small number
of cytokines.
Limitations of our study include the cross-sectional de-
sign. Our study population consisted of primarily Caucasian
men and may not be generalizable to non-white men and
women. We developed an inflammatory burden score by
calculating the number of pro-inflammatory cytokines in
the highest quartile. However, this approach yielded an
uneven number of men in each group. For example, the
number of men with 2 high inflammatory cytokines
was much smaller than the other groups and CI were
wide. Finally, we had no information on clinical signs
and symptoms of PAD.
Conclusions
In conclusion, individual pro-inflammatory cytokines
and overall inflammatory burden are associated with
prevalent PAD, an association similar to aging 10 years.
The inflammatory effects of smoking at least partially
mediates this association. To our knowledge we are the
first to relate inflammatory burden to prevalent PAD,
which could be expanded upon in the future as more
cytokines/biomarkers are discovered, and the assays
become faster, more sensitive, and less expensive. Future
studies on incident PAD in the setting of various inflam-
matory profiles may allow us predict disease and intervene
before there is significant morbidity.
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